Literature DB >> 31472880

The Evolution from Hypertension to Heart Failure.

Matthew J Sorrentino1.   

Abstract

Hypertensive heart disease includes the development of diastolic dysfunction, left ventricular hypertrophy, and heart failure with preserved and reduced ejection fraction. The development of heart failure can occur because of complications of ischemic heart disease or from progression of diastolic dysfunction to heart failure with preserved ejection fraction degenerating to a dilated heart with systolic dysfunction or heart failure with reduced ejection fraction. Hypertension clinical trials have shown that the treatment of hypertension can prevent the development of heart failure. In addition, lifestyle modification with exercise and weight loss can improve diastolic function and reduce the risk for heart failure.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diastolic dysfunction; Heart failure with preserved ejection fraction (HFpEF); Heart failure with reduced ejection fraction (HFrEF); Left ventricular hypertrophy (LVH)

Year:  2019        PMID： 31472880     DOI： 10.1016/j.hfc.2019.06.005

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN： 1551-7136            Impact factor:   3.179


  9 in total

Review 1.  Hypertensive Heart Failure in Asia.

Authors:  Helsi Rismiati; Hae-Young Lee
Journal:  Pulse (Basel)       Date:  2021-10-11

2.  A New Minimally Invasive Method of Transverse Aortic Constriction in Mice.

Authors:  Huayang Li; Quan Liu; Shunjun Wang; Lin Huang; Suiqing Huang; Yuan Yue; Kangni Feng; Zhongkai Wu
Journal:  J Cardiovasc Transl Res       Date:  2021-09-08       Impact factor: 3.216

3.  Aortic Stiffness and Diastolic Dysfunction in Sprague Dawley Rats Consuming Short-Term Fructose Plus High Salt Diet.

Authors:  Dragana Komnenov; Peter E Levanovich; Natalia Perecki; Charles S Chung; Noreen F Rossi
Journal:  Integr Blood Press Control       Date:  2020-09-28

4.  Association of Office and Ambulatory Blood Pressure with Left Ventricular Structure and Function in Hypertensive Patients.

Authors:  Zhuo Sang; Xianli Zeng; Xiaohui Yuan; Xiaolin Wang; Liancong Fu; Wenwen Zhuang
Journal:  Int J Gen Med       Date:  2022-05-04

Review 5.  A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension.

Authors:  Li Zheng; Binbin Xia; Xuqian Zhang; Yan Zhao
Journal:  Cardiol Res Pract       Date:  2021-03-20       Impact factor: 1.866

6.  Vasorelaxant-Mediated Antihypertensive Effect of the Leaf Aqueous Extract from Stephania abyssinica (Dillon & A. Rich) Walp (Menispermaceae) in Rat.

Authors:  Chamberlin Fodem; Elvine Pami Nguelefack-Mbuyo; Magloire Kanyou Ndjenda Ii; Albert Kamanyi; Télesphore Benoit Nguelefack
Journal:  Biomed Res Int       Date:  2021-10-08       Impact factor: 3.411

7.  Cardioprotective Effect of Paeonol on Chronic Heart Failure Induced by Doxorubicin via Regulating the miR-21-5p/S-Phase Kinase-Associated Protein 2 Axis.

Authors:  Cong Chen; Shuhong Liu; Gaozhen Cao; Yang Hu; Run Wang; Min Wu; Mingya Liu; Kai Hang Yiu
Journal:  Front Cardiovasc Med       Date:  2022-07-05

8.  Correlation analysis of the triglyceride glucose index and heart failure with preserved ejection fraction in essential hypertensive patients.

Authors:  Li Ping Liao; Yang Yang; Yilin Wu; Weizhen Li
Journal:  Clin Cardiol       Date:  2022-06-29       Impact factor: 3.287

9.  Concept of myocardial fatigue in reversible severe left ventricular systolic dysfunction from afterload mismatch: a case series.

Authors:  Patrick Tran; Mithilesh Joshi; Prithwish Banerjee
Journal:  Eur Heart J Case Rep       Date:  2021-03-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.